CA2303395C - Treatment of obesity - Google Patents

Treatment of obesity Download PDF

Info

Publication number
CA2303395C
CA2303395C CA002303395A CA2303395A CA2303395C CA 2303395 C CA2303395 C CA 2303395C CA 002303395 A CA002303395 A CA 002303395A CA 2303395 A CA2303395 A CA 2303395A CA 2303395 C CA2303395 C CA 2303395C
Authority
CA
Canada
Prior art keywords
peptide
hgh
seq
cys
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002303395A
Other languages
English (en)
French (fr)
Other versions
CA2303395A1 (en
Inventor
Frank Man-Woon Ng
Woei-Jia Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Pharmaceuticals Pty Ltd
Original Assignee
Metabolic Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO9001A external-priority patent/AUPO900197A0/en
Priority claimed from AUPP0398A external-priority patent/AUPP039897A0/en
Application filed by Metabolic Pharmaceuticals Pty Ltd filed Critical Metabolic Pharmaceuticals Pty Ltd
Publication of CA2303395A1 publication Critical patent/CA2303395A1/en
Application granted granted Critical
Publication of CA2303395C publication Critical patent/CA2303395C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Photolithography (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Percussion Or Vibration Massage (AREA)
CA002303395A 1997-09-08 1998-09-04 Treatment of obesity Expired - Lifetime CA2303395C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPO9001 1997-09-08
AUPO9001A AUPO900197A0 (en) 1997-09-08 1997-09-08 Treatment of obesity
AUPP0398 1997-11-13
AUPP0398A AUPP039897A0 (en) 1997-11-13 1997-11-13 Treatment of obesity
PCT/AU1998/000724 WO1999012969A1 (en) 1997-09-08 1998-09-04 Treatment of obesity

Publications (2)

Publication Number Publication Date
CA2303395A1 CA2303395A1 (en) 1999-03-18
CA2303395C true CA2303395C (en) 2008-12-02

Family

ID=25645599

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303395A Expired - Lifetime CA2303395C (en) 1997-09-08 1998-09-04 Treatment of obesity

Country Status (12)

Country Link
US (2) US6737407B1 (enExample)
EP (1) EP1012189B1 (enExample)
JP (1) JP4334761B2 (enExample)
CN (1) CN1195776C (enExample)
AT (1) ATE377026T1 (enExample)
BR (1) BR9811755A (enExample)
CA (1) CA2303395C (enExample)
DE (1) DE69838647T2 (enExample)
ES (1) ES2296342T3 (enExample)
NZ (1) NZ502993A (enExample)
RU (1) RU2223970C2 (enExample)
WO (1) WO1999012969A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ387599A0 (en) 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005007859A2 (en) * 2003-07-11 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP4931802B2 (ja) * 2004-05-04 2012-05-16 メタボリック・ファーマシューティカルズ・リミテッド 骨障害を予防または治療するための方法
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
JP2009502976A (ja) * 2005-08-02 2009-01-29 メタボリック・ファーマシューティカルズ・リミテッド 親水性ペプチド鎮痛薬の経口送達のためのペプチドコンジュゲート
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
WO2008098280A1 (en) * 2007-02-16 2008-08-21 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of dicarba bridges in growth hormone peptides
EP2340050A2 (en) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of aod-like peptides
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
CN110448683A (zh) * 2011-12-09 2019-11-15 麦特保利药业有限公司 生长激素片段的用途
CN102827290A (zh) * 2012-09-07 2012-12-19 浙江大学 人血清白蛋白与人生长激素脂肪分解结构域的融合蛋白
GB2507341A (en) * 2012-10-29 2014-04-30 Peter Kenny Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone
WO2019136528A1 (en) * 2018-01-15 2019-07-18 Lateral IP Pty Ltd Peptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG49718A3 (bg) 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US4863901A (en) 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity

Also Published As

Publication number Publication date
CA2303395A1 (en) 1999-03-18
US6737407B1 (en) 2004-05-18
DE69838647D1 (de) 2007-12-13
JP2002501004A (ja) 2002-01-15
EP1012189A4 (en) 2004-10-20
CN1275132A (zh) 2000-11-29
EP1012189B1 (en) 2007-10-31
ATE377026T1 (de) 2007-11-15
CN1195776C (zh) 2005-04-06
JP4334761B2 (ja) 2009-09-30
EP1012189A1 (en) 2000-06-28
WO1999012969A1 (en) 1999-03-18
BR9811755A (pt) 2000-08-29
NZ502993A (en) 2002-12-20
DE69838647T2 (de) 2008-08-28
US20040192608A1 (en) 2004-09-30
RU2223970C2 (ru) 2004-02-20
ES2296342T3 (es) 2008-04-16

Similar Documents

Publication Publication Date Title
CA2303395C (en) Treatment of obesity
US5869452A (en) Treatment of obesity
CA1236012A (en) Pharmaceutical agent for the treatment of diabetes mellitus
Yasuda et al. Primary structure of chum salmon prolactins: Occurrence of highly conserved regions
AU2005224028B2 (en) Y4 selective receptor agonists for therapeutic interventions
NO179587B (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv insulinanalog og mellomprodukt
HU211856A9 (en) Peptides
JPS60260595A (ja) Ｇｒｆ類似体
AU2011208620B2 (en) Stable growth hormone compounds
US20090118178A1 (en) Y4 selective receptor agonists for therapeutic interventions
CA2083360A1 (en) Tri-arginine insulins
KR900006713B1 (ko) Grf 유사체 펩티드의 제법
AU654195B2 (en) GRF analogs XI
HU206375B (en) Process for producing biologically active, stable somatotropins and pharmaceutical compositions comprising same as active ingredient
US20090186811A1 (en) Y2 Selective Receptor Agonists for Therapeutic Interventions
US20080261871A1 (en) Y2/Y4 Selective Receptor Agonists for Therapeutic Interventions
Su et al. In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma
Kostyo The search for the active core of pituitary growth hormone
EP0773958A1 (en) PTH OR PTHrP ANTAGONISTS
AU755512B2 (en) Treatment of obesity
US6335319B1 (en) Treatment of obesity
AU2007200203A1 (en) Treatment of obesity
US20060069026A1 (en) Treatment of obesity
RU2130945C1 (ru) Птг-соединения и способ их получения, содержащая их фармацевтическая композиция, фрагмент днк и слитый белок
CZ186492A3 (en) Insulin analog, process of its preparation and a pharmaceutical composition containing thereof

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180904